Saturday, March 28, 2026 2:38:18 PM
It's just another Distribution Deal. Mayer will buy 25,000 units soon, price around $10 a pop, generating about $250,000 gross revenues for Kelly.
Considering that CICD Shenzhen has to register with the FDA again (they currently are not), then manufacture and ship the devices, it's unlikely that Mayer will get his 25,000 units before May and get his units in stores before June. I'll be surprised if he sells those 25,000 units fast enough to order much more in 2026 -- maybe another 25,000 units, for a total of $500k gross revenues for BIEL. Add that to whatever else Kelly can sell -- maybe a couple hundred K -- and it's going to be another losing year for BIEL with under $1M gross revenues.
According to the Distribution Agreement, in order to maintain exclusivity, Mayer is supposed to buy 100,000 units in 2026. That's not going to happen, but who cares -- Kelly won't enforce that exclusivity clause because nobody else is trying to sell in the US anyway. Kelly and Rick know that Mayer is their last and only chance.
Mayer plans to sell ActiPatches at $50 each. Interesting to see how that works out.
Mayer said in his promotion materials that he had raised $400,000 from Angel Investors and wants another $500,000 in his SPV. Apparently he's raised another $100k since then, and now has $500k. Even if he gets his $900k. that's not going to create much of a marketing campaign after he lays out $250,000 for his initial stocking order.
Everything Misanthrope said is true. Mayer admitted that there's nothing AI about the ActiPatch, and it will not be modified except for packaging. Mayer is focusing on his SofPulse clone with the VA and CMS. He might even get FDA clearance by the end of 2026, which would mean he probably won't be selling RecoveryRx. There is no reimbursement for OTC products like aspirin and bandaids and ActiPatches.
So Mayer wants to peddle ActiPatches OTC for some fast money while he develops his AI apps and SofPulse clone. Let's all wish him the best of luck.
The bid's going to be at .0002 next week. oh well, at least this MB is getting millions of views. That's more important than the PPS.
BIEL
Considering that CICD Shenzhen has to register with the FDA again (they currently are not), then manufacture and ship the devices, it's unlikely that Mayer will get his 25,000 units before May and get his units in stores before June. I'll be surprised if he sells those 25,000 units fast enough to order much more in 2026 -- maybe another 25,000 units, for a total of $500k gross revenues for BIEL. Add that to whatever else Kelly can sell -- maybe a couple hundred K -- and it's going to be another losing year for BIEL with under $1M gross revenues.
According to the Distribution Agreement, in order to maintain exclusivity, Mayer is supposed to buy 100,000 units in 2026. That's not going to happen, but who cares -- Kelly won't enforce that exclusivity clause because nobody else is trying to sell in the US anyway. Kelly and Rick know that Mayer is their last and only chance.
Mayer plans to sell ActiPatches at $50 each. Interesting to see how that works out.
Mayer said in his promotion materials that he had raised $400,000 from Angel Investors and wants another $500,000 in his SPV. Apparently he's raised another $100k since then, and now has $500k. Even if he gets his $900k. that's not going to create much of a marketing campaign after he lays out $250,000 for his initial stocking order.
Everything Misanthrope said is true. Mayer admitted that there's nothing AI about the ActiPatch, and it will not be modified except for packaging. Mayer is focusing on his SofPulse clone with the VA and CMS. He might even get FDA clearance by the end of 2026, which would mean he probably won't be selling RecoveryRx. There is no reimbursement for OTC products like aspirin and bandaids and ActiPatches.
So Mayer wants to peddle ActiPatches OTC for some fast money while he develops his AI apps and SofPulse clone. Let's all wish him the best of luck.
The bid's going to be at .0002 next week. oh well, at least this MB is getting millions of views. That's more important than the PPS.
BIEL
